ABSTRACT
Short-term calorie reduction (SCR) requires individuals to reduce their calorie intake to less than 50% of normal requirements and has shown good tolerance and potential benefits in prior studies addressing gynecological cancer patients. More studies are needed to further confirm its safety, feasibility, and effects in patients with different cancers, including hematological malignancies. This pilot cohort study with a matched-pair comparison group was registered at ClinicalTrails.gov [201810112RIND]. Adult patients diagnosed with advanced-stage diffuse large-B cell lymphoma were recruited (SCR group) and matched with one comparison patient (comparison group), each in a manner blinded to their outcomes. The SCR group undertook at least two cycles of 48 h water fast along with their chemotherapy R-CHOP. Descriptive analysis and generalized estimating equations were used to analyze the data. Six participants completed multiple cycles of SCR and were compared to their six counterparts in the comparison group. The results showed that SCR is safe and feasible in terms of a high compliance rate and stable nutritional status. The SCR was associated with benefits in post-chemotherapy hematological parameters (i.e., erythrocyte [p < 0.001] and lymphocyte counts [p < 0.001]). More randomized controlled trials are needed to validate the effects of SCR on different types of cancer populations.
Subject(s)
Caloric Restriction/methods , Induction Chemotherapy/methods , Lymphoma, Large B-Cell, Diffuse/drug therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Caloric Restriction/adverse effects , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Feasibility Studies , Female , Humans , Lymphoma, Large B-Cell, Diffuse/diet therapy , Male , Matched-Pair Analysis , Middle Aged , Pilot Projects , Prednisone/administration & dosage , Prednisone/adverse effects , Prednisone/therapeutic use , Rituximab/administration & dosage , Rituximab/adverse effects , Rituximab/therapeutic use , Treatment Outcome , Vincristine/administration & dosage , Vincristine/adverse effects , Vincristine/therapeutic useABSTRACT
Lisocabtagene maraleucel (Breyanzi), a personalized cell-based gene therapy, has been approved to treat adults with various relapsed or refractory large B-cell lymphomas.
Subject(s)
Antigens, CD19/therapeutic use , Lymphoma, Large B-Cell, Diffuse/therapy , Molecular Targeted Therapy/methods , Precision Medicine/methods , Biological Products , Humans , Immunotherapy, Adoptive , Lymphoma, Large B-Cell, Diffuse/diet therapyABSTRACT
Nuclear magnetic resonance (NMR) spectroscopy and multivariate data analyses methods are applied to the metabolic profiling of different red wines from Portugal. The water, methanol-water (1:1), and methanol fractions from solid phase extraction (SPE) with C18 resin were subjected to in vitro TNFα activity assay. Principal component analysis allowed the clear separation among the different SPE fractions according to the activity. Various supervised data reduction algorithms were tested and compared to highlight the TNFα inhibition by SPE fractions of wines. Partial least squares-discriminant analysis and orthogonal bidirectional PLS-DA were found most effective in discriminating the samples with different activities. By calculating variable importance in the projection, the active ingredients in the high activity samples have been identified as caftaric acid, quercetin, and catechin. Among the different vintages, samples from 2010 vintage were found with maximum anti-TNFα activity. The effectiveness of NMR spectroscopy in combination with chemometrics to identify the possible bioactivity in the several crude extracts is highlighted.
